Skip to content

Released Aug 15, 2022, before the open

10-Q filed Aug 15, 2022, 46 days after period end · 0001558370-22-013560

Q2 2022 · 10-Q
Revenue$8.75M+36.2% vs Q2 2021−45.6% vs Q1 2022
Net Income-$5.33MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.11N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$5,524,000N/M
Operating Cash Flowderived-$7,356,000N/M
Free Cash Flowderived-$7,484,000N/M
Margins · derived
Operating margin-63.1%+79.5 pt vs Q2 2021
Net margin-60.9%+114.0 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Revenue$8.75M$6.43M$10.97M$12.25M
Net Income-$5.33M-$11.24M-$4.15M-$7.74M
EPS Diluted-$0.11-$0.25-$0.13-$0.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR